Making Part D Stick: Lessons From the First Year of Medicare Rx
This article was originally published in RPM Report
Executive Summary
Medicare beneficiaries stuck with their Part D plans heading into 2007. That gives insurers more leverage in price negotiations with big pharma. It also means Part D may be more likely to stick around despite critics in the Democratic Congress.
You may also be interested in...
Medicare Rx at a Turning Point: Big Plans Stumble as Part D Enters a Pivotal Year
United, Humana and especially WellCare are taking their licks in the run-up to the third year of the Medicare prescription drug program. That is just the latest warning sign for pharma and biotech companies that a critical market is entering a critical turning point.
Medicare Rx at a Turning Point: Big Plans Stumble as Part D Enters a Pivotal Year
United, Humana and especially WellCare are taking their licks in the run-up to the third year of the Medicare prescription drug program. That is just the latest warning sign for pharma and biotech companies that a critical market is entering a critical turning point.
With Enemies Like These: Will the Democrats Make Part D More Pharma Friendly?
The Democratic leadership rammed a major health bill through the House this summer, including some Medicare Part D fixes that read like a Big Pharma wish list. Have the industry's toughest critics gone soft?